Preliminary Injunction Granted to Enforce Revvity’s Rights and Cloud Software Group’s Obligations Related to Spotfire Software

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has granted a preliminary injunction compelling Cloud Software Group (CSG) to comply with its contractual obligations under its strategic partner agreements with Revvity, including an order to cease all marketing, selling and support activities in Revvity’s exclusive markets and to continue delivering maintenance services to Revvity in relation to its Spotfire^® software.

This decision comes after Revvity filed a lawsuit against CSG, alleging unfair business practices and breach of contract. The preliminary injunction ensures uninterrupted service to Revvity and its customers of Spotfire software, safeguarding their operational continuity and service quality. Revvity remains dedicated to upholding the highest standards of service delivery and customer satisfaction that it has been delivering to Spotfire customers for over a decade.

"We are pleased with the court's decision to grant the preliminary injunction," said Kevin Willoe, SVP and general manager at Revvity Signals Software. "This ruling underscores the strength of our legal position in this matter and, more importantly, the importance of Revvity’s domain knowledge and expertise in serving our valued customers as they advance their science. Revvity remains steadfast in our commitment to providing unparalleled service excellence."

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.